Mohammad M. Sajadi, MD, is Professor of Medicine and Associate Professor of Medicine in the Division of Clinical Care and Research at the Institute of Human Virology, University of Maryland School of Medicine. Based in Baltimore, he directs a translational research program focused on HIV-1 humoral immunity and SARS-CoV-2 immunology. Education & Training: While the provided text does not list explicit degrees, his MD title indicates medical training followed by specialty and research training in infectious diseases and virology. Research Interests: Dr. Sajadi’s laboratory studies the molecular basis of broadly neutralizing antibody responses against HIV-1, with particular attention to elite controllers who suppress virus without therapy. The group engineers next-generation monoclonal antibodies for improved potency, manufacturability, and CNS delivery. Parallel efforts dissect SARS-CoV-2 immunity, exploring antibody durability, mucosal protection, and environmental influences on COVID-19 mortality. Publication Trends: Across >50 recent papers, a clear trajectory emerges: early work defined signatures of broad HIV neutralization in plasma, followed by mechanistic studies on λ-light-chain bias and memory B-cell responses. Recent outputs pivot toward translational development—liposomal antibody delivery, glial progenitor-based gene therapy for HIV brain reservoirs, and multiplex serology platforms. COVID-19 studies mirror this translational depth, covering vaccine immunogenicity, maternal antibody transfer, and climate-linked epidemiology. Scientific Recognition: While no specific awards are listed, sustained NIH and institutional funding, high-impact publications in J Infect Dis , J Virol , PNAS , and invited reviews in 2020-2025 collectively underscore international recognition in HIV and COVID-19 antibody research. Grants & Collaborations: Dr. Sajadi leads multi-disciplinary teams spanning virology, structural biology, and pharmacology. Active collaborations include the NIAID-funded Consortia for HIV/AIDS Vaccine Development, the Global COVID-19 Convalescent Plasma Project, and industry partnerships for antibody manufacturing scale-up. Laboratory & Teams: The Sajadi Laboratory is housed within the Institute of Human Virology, occupying state-of-the-art BSL-2/3 space. Core teams include post-doctoral fellows, graduate students, research technicians, and computational biologists working on antibody engineering, single-cell B-cell repertoire analysis, and in vivo challenge models.


